PBM Legislation and the PBM-affiliated GPOs | AMCP 2024

After the onboarding of cell and gene therapy bogged using normal pharmacy and therapeutics (P&T) committee procedures, UC Davis Health set up an emerging therapeutics committee to streamline and speed up the process of delivery expensive cell and gene therapies.

Spending on the GLP-1 class of therapeutics is expected to grow by 378% to $8.1 billion by 2027.

Up to 50 generics could be approved this year, including Victoza to treat patients with diabetes. If generics of Victoza become available, this would the first GLP-1 to face generic competition.

One result of the Inflation Reduction Act shifting a greater proportion the cost of drugs during the catastrophic phase of coverage to the Part D plans result may be narrower formularies.

Innovative contracts are becoming more common for gene therapies. They aim to balance a therapy’s cost-effectiveness and affordability, as well as address the uncertainty of long-term benefit.

Adam Colborn outlined four trends in state-level action on pharmacy benefit managers (PBMs) and drugs in an interview prior to this presentation at the annual meeting of Academy of Managed Care Pharmacy (AMCP) today.